Welireg

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

News

MSD trims outlook as it aims to shave $3bn off costs

MSD is embarking on a $3bn cost-reduction drive to prepare for the loss of patent protection for cancer blockbuster Keytruda.

News

MSD adds new indication for Welireg in rare tumours

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.

News

NICE clears NHS use of MSD's Welireg for genetic disorder

Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland.

News

MSD claims 2nd FDA approval for Welireg, in kidney cancer

The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common f

News

Scotland first in Europe to back MSD drug for VHL tumours

Scotland has become the first country in Europe to recommend coverage of MSD’s Welireg as a treatment for some people with von Hippel-Lindau disease (VHL), a rare genetic

MSD, Eisai abandon combination trial in liver cancer

MSD trims outlook as it aims to shave $3bn off costs

MSD adds new indication for Welireg in rare tumours

NICE clears NHS use of MSD's Welireg for genetic disorder

MSD claims 2nd FDA approval for Welireg, in kidney cancer

Scotland first in Europe to back MSD drug for VHL tumours

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Welireg

Editor's Picks